Company Profile
Benitec Biopharma Stock Price, News & Analysis
- Ticker:
- BNTC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Australia and listed in the U
Stock performance
11.58 USD (+0.96%)
Close
Last updated: July 27, 2026
363M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, BNTC closed up 0.96% at $11.58. No new same-company headline was identified in the current news window.
Company overview
Business overview
Benitec Biopharma is a gene-silencing biotechnology company focused on DNA-directed RNA interference and genetic medicine. Its story is built around platform science that aims to durably suppress disease-causing genes.
Geographic Base and Sector Classification
Benitec is headquartered in Australia and listed in the U.S. market. It sits in gene therapy and genetic medicine biotechnology.
Business Model Characteristics
The business depends on translational validation, clinical milestones, and the ability to keep a narrow platform funded. Investors watch early data and strategic collaborations.
Position Within the Biotechnology Landscape
Benitec occupies a gene-silencing niche within biotech. The stock is driven by whether the platform can prove durable and differentiated genetic medicine potential.
Future catalysts
The next few months for Benitec Biopharma are centered on BB-301. The latest company update points to continued work around BB-301 and the next company-specific development update. If that progress holds, the program should stay on the radar through the rest of the quarter.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
- 02
- 03
- 04
Viðskipti stjórnenda og tengdra aðila
ALVO · Source: Alvotech
- 05
Transactions of Managers and Closely Associated Persons
ALVO · Source: Alvotech
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Benitec Biopharma (BNTC)?
Benitec Biopharma (BNTC) most recently closed at 11.58 USD, a +0.96% move versus the previous session.
What is the market cap of Benitec Biopharma (BNTC)?
Benitec Biopharma currently has a market capitalization of 363M USD on BioPharmSignal.
What does Benitec Biopharma do?
Benitec Biopharma is a gene-silencing biotechnology company focused on DNA-directed RNA interference and genetic medicine. Its story is built around platform science that aims to durably suppress disease-causing genes.
On which exchange is BNTC stock listed?
Benitec Biopharma (BNTC) is associated with NASDAQ, Australia and listed in the U, Biopharma.
What is BB-301?
The next few months for Benitec Biopharma are centered on BB-301.
Which conditions is Benitec Biopharma targeting with BB-301?
Benitec Biopharma is associated with genetic disease based on its company overview and current catalyst commentary.
How does Benitec Biopharma describe recent progress with BB-301?
The next few months for Benitec Biopharma are centered on BB-301.
What is Benitec?
Benitec Biopharma is a gene-silencing biotechnology company focused on DNA-directed RNA interference and genetic medicine.